Protein and peptide biopharmaceuticals: An overview
dc.contributor.author | Agyei, D. | |
dc.contributor.author | Ahmed, I. | |
dc.contributor.author | Akram, Z. | |
dc.contributor.author | Iqbal, H. | |
dc.contributor.author | Danquah, Michael | |
dc.date.accessioned | 2018-12-13T09:16:01Z | |
dc.date.available | 2018-12-13T09:16:01Z | |
dc.date.created | 2018-12-12T02:46:36Z | |
dc.date.issued | 2017 | |
dc.identifier.citation | Agyei, D. and Ahmed, I. and Akram, Z. and Iqbal, H. and Danquah, M. 2017. Protein and peptide biopharmaceuticals: An overview. Protein and Peptide Letters. 24 (2): pp. 94-101. | |
dc.identifier.uri | http://hdl.handle.net/20.500.11937/73264 | |
dc.identifier.doi | 10.2174/0929866523666161222150444 | |
dc.description.abstract |
© 2017 Bentham Science Publishers. Bioactive proteins and peptides are recognised as novel therapeutic molecules with varying biological properties for potential medical applications. Development of protein and peptidebased therapeutic products for human use is growing steadily as they continue to receive an increasing rate of approval by the United States Food and Drugs Administration (US FDA). In this short review, we describe the current status and methodologies involved in the synthesis of protein and peptide biopharmaceuticals with an emphasis on the drivers and restrains to their exploitation in the therapeutic products sector. | |
dc.title | Protein and peptide biopharmaceuticals: An overview | |
dc.type | Journal Article | |
dcterms.source.volume | 24 | |
dcterms.source.number | 2 | |
dcterms.source.startPage | 94 | |
dcterms.source.endPage | 101 | |
dcterms.source.issn | 0929-8665 | |
dcterms.source.title | Protein and Peptide Letters | |
curtin.department | Curtin Malaysia | |
curtin.accessStatus | Fulltext not available |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |